After successfully completing Phase III trials of oral insulin, China s Hefei Tianhui Biotechnology (HTIT) submitted a marketing authorisation application (MAA) to the country s National Medical Products Administration.Oram
ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top
The presentation will be webcasted and can be viewed through the following link for up to 90 days following the presentation: https://cc.webcasts.com/barc002/031522a js/?entity=92 X7NI2JC.
Oravax Medical has taken an early step toward the commercialization of its oral COVID-19 vaccine by entering into a deal to ship 10 million doses of the clinical-phase candidate to Southeast Asia.
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately